Kinases regulate cell growth, movement, and death. Deregulated kinase activity is a frequent cause of disease. The therapeutic potential of kinase inhibitors has led to large amounts of published structure activity relationship (SAR) data. Bioactivity databases such as the Kinase Knowledgebase (KKB), WOMBAT, GOSTAR, and ChEMBL provide researchers with quantitative data characterizing the activity of compounds across many biological assays. The KKB, for example, contains over 1.8M kinase structure-activity data points reported in peer-reviewed journals and patents. In the spirit of fostering methods development and validation worldwide, we have extracted and have made available from the KKB 258K structure activity data points and 76K associated unique chemical structures across eight kinase targets. These data are freely available for download within this data note.
Since their discovery in 1975 by Cohen et al. 1 , kinases are now one of the most established drug target families, second only to G-protein-coupled receptors (GPCRs). Most progress in kinase research has occurred in the last 25 years including the discovery of many new kinases 2,3 , identification of new isoforms of preexisting kinases 4,5 , elucidation of new biological pathways, and identification of many new kinase-disease associations 6,7 . While kinases are well-validated anti-cancer targets [8] [9] [10] [11] , kinase inhibitors also have been pursued in cardiovascular 12 , autoimmune 13 , inflammatory skin and bowel 14 , neurodegenerative 15 , and renal disease programs 16 . Most small-molecule kinase inhibitors target the ATP binding site of the kinase catalytic domain 11 . The ATP binding region of the catalytic domain is highly conserved among protein kinases, which has important consequences for drug development. Achieving selectivity of a small molecule inhibitor against kinase off-targets to avoid adverse reactions can be a major hurdle. However, the cross reactivity of many chemotypes can also open opportunities to focus on other closely related kinases. Despite the high degree of conservation in the ATP binding site, reasonably selective inhibitors with favorable pharmacological properties can be developed 17 . It is now common in discovery programs to profile inhibitors against an extensive set of kinase targets 18 . These kinase-profiling efforts have generated valuable data, providing insight into selectivity and promiscuity of clinical inhibitors 19-21 .
Medicinal chemists can benefit significantly from well-curated databases documenting chemical structure(s) with an experimentally measured biological activity. These structure and activity databases or SAR databases help to better understand drug-target interaction, which can assist in the design of potent and selective chemical inhibitors 22-25 . A well populated, editable, easy to search and flexible SAR database is an integral part of the modern drug design process 26 . SAR databases provide elementary insights to researchers, including:
(a) Target druggability: known small molecule binders are required to categorize a protein as druggable. High-affinity and non-promiscuous inhibitors are particularly valuable to establish druggability; and can be further validated using structure biology information. In many cases druggability can be inferred for new targets using homology models 27 where similarities can be mapped via sequences, pathways or functions. Examples include the Target Informatics Platform (TIP) 28 and Modbase 29 .
(b) Scaffold selectivity: the golden principle that applies is "less selective scaffolds have more undesirable side effects." A prior knowledge of selectivity profiles can help in making informed decisions on which chemotypes to pursue at the start of discovery programs 30 . Organizing data by scaffold enables classic SAR analysis in which side-chain moieties can be evaluated and considered or avoided in lead optimization 31 .
(c) Clinical molecules: it can be very helpful to see scaffold(s) or derivatives under the study of launched drugs. This enables medicinal chemists to associate therapeutic classes with active scaffolds.
(d) Development and validation of computational methods: well-curated datasets are very helpful in the development and refinement of computational methodologies. With a common set of data, computational researchers can also compare and contrast methods, providing additional validation 32 .
(e) Virtual screening: high-quality, well-curated, standardized and annotated datasets are required to build predictive models for virtual screening as we have shown previously specifically for the Kinase Knowledgebase (KKB) data 33 .
Materials and Methods
The KKB is a database of biological activity data, structureactivity relationships, and chemical synthesis data focused on protein kinases. Since its inception in 2001, the KKB has grown steadily with quarterly updates each year. With more than two decades of high quality SAR data, the KKB represents one of the first kinase target specific databases of biological activity and chemical synthesis data from curated scientific literature and patents. The KKB contains a large number of kinase structure-activity data points (>1.8M) reported in peer-reviewed literature covering journals and patents. The data have been curated from over 150 different journals reporting kinase inhibitors with activity data, with leading contributions from J Med Chem, Bioorg Med Chem, Bioorg Med ChemLett and Euro J Med Chem. In addition, the KKB contains data curated from patents/applications from WO, EP and US. The scientific information is curated from the published text using a combination of automatic and manual efforts.
A summary of the first quarter release for year 2016 (Q1-2016) is reported in Table 1 . With the Q1-2016 KKB release, there are total of 506 unique kinase targets with over 682K unique small molecules. A listing of few "hot" kinase targets with their inhibitors (data points) is reported in Table 2 . 
Amendments from Version 2
In this version, the figures have undergone minor cosmetic changes. Kinase inhibitors are biologically active small molecules and their activity refers to experimentally measured data on a given kinase target (in enzyme or in cell based assays), using predefined experimental protocols. After curation and standardization, these measured values together with related information are indexed in the KKB. Each inhibitor entered in the KKB carries unique identifiers such as: (c) Experimental bioactivity screening results. A bioactivity data point is a defined result/endpoint of a specified small molecule compound tested in a biological assay. The assay is defined in b); result type/endpoint captured include IC 50 , K i , K d ; the vast majority for biochemical and cell-based assays correspond to BAO definitions.
See referee reports

REVISED
(d) Source reference: bibliographic information and unique identifiers for journal article and patents from which information related to the molecules was extracted include PubMedID, DOI, and standardized patent numbers. For journals, the KKB provides title, authors name, journal-name, volume, issues, and page numbers. For patents their titles, patent or patent application number (along with family members), inventor's names, assignee names, publication data and priority numbers are provided.
It is observed that a disease type can be related to multiple kinase groups, and several diseases can arise from a common set of kinase group (Table 3) non-protein kinases with several sub-categories such as carbohydrate and lipid kinase and the typical protein kinase groups (such CMGC, CAMK, TK, TKL, RGC, AGC) and further sub-groups such as families. DTO provides a functional and phylogenetic classification of kinase domains to facilitate navigation of kinase drug targets. DTO is developed as part of the Illuminating the Druggable Genome (IDG) project. Here we make datasets freely available for the research community including to support efforts such as IDG. We also offer to run our predictive models built using KKB data to support prioritization of drug targets.
Kinase inhibitor datasets
The wealth of kinase inhibitor data presents opportunities for analysis as a whole or by integrating such data into various computational platforms to support development and validation of hypotheses of kinase inhibition. Several years ago, Eidogen-Sertanty made available 3880 pIC 50 data points across three kinase targets (ABL1, SRC, and AURKA -validation sets) to foster algorithm development and validation worldwide. With this data note, eight additional targets comprising inhibitors for therapeutically important classes: EGFR, CDK2, ROCK2, MAPK14 and PI3K (class I catalytic) ( The datasets cover a broad range of biochemical and cell based studies investigating kinase inhibition; and they represent a diverse collection of pharmaceutically active scaffolds. These scaffolds can be easily examined for selectivity and specificity for the given eight kinase targets. Additionally, they can be used to infer novel targetinhibitor relationships for kinases and compounds not included in these subsets.
Bibliographic information is reported in the files ArticleInfo_F1000. txt and PatentInfo_F1000.txt. Experimental procedure along with metadata information for targets including EntrezGeneIDs, assay format/type (biochemical/enzyme, cell based, etc), keywords, species, and cell lines used in cell-based data are stored in AssayProtocols_F1000 (txt and xml attached).
The KKB validation sets have a maximum contribution from EGFR with nearly ~54K inhibitor molecules. This is followed by ~43K inhibitors for MAPK14; CDK2 and PIK3CA each have ~39K inhibitors. Figure 1 depicts data point distributions for each kinase in the attached subset. Moreover, 84% of the data are from biochemical enzyme based assay experiments, and 16% of the data from cell-based assays (in Figure 2) . The datapoint measures include IC 50 , K i and K d (Figure 3 ). Analysis of ~76K unique molecules for selectivity against targets reveals that ~64K inhibit only one kinase of the eight kinases extracted (Figure 4 ). Approximately 5K molecules show activity against two kinase targets, and ~3K molecules show activity against three kinases. A total of 79 molecules in the subset have some activity against all the eight kinase targets. 
Conclusions
The KKB is available in various formats such as SQL, SDF and IJC format (Instant JChem) as quarterly updates. Two mobile apps, iKinase and iKinasePro 25 , are also available for download which enable basic search access into KKB content, including kinase inhibitor structures, biological data and references/patents. Simple substructure and exact structure search access into the KKB is also available. We have extracted from the KKB ~258K structure activity data points and ~76K associated unique chemical structures across eight kinase targets and made these data freely available for download within this data note to foster algorithms development and validation worldwide.
Data availability
F1000Research: Dataset 1. High quality, small molecule-activity for kinase research, 10.5256/f1000research.8950.d124591 36 1.
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general, the amount of bioactivity data, coming from various sources (scientific literature, high-throughput screening results, patents etc), is heterogeneous and a proper curation and standardization of the data can provide reliable activity points. These data may be employed in many ways as described by the authors. In my opinion, the main applications for a database such as KKB would be to build predictors to search the chemical space for new kinase inhibitors, and further to optimize the selectivity of kinase inhibitors. Currently, ChEMBL's publicly available Kinase SARfari ( ), provides a standard source for these tasks, covering https://www.ebi.ac.uk/chembl/sarfari/kinasesarfari about 532155 bioactivity data points i.e., version: 6.00-accessed June 20, 2016. This is less than one third of the 1.8 million KKB activity data point reported by the authors. In these circumstances, KKB might add valuable information for kinase research. Finally, the future analysis and employment of the eight data sets made freely available in the current note will provide a clearer view of the potential and versatility of KKB.
There would be two minor observations:
The methodology used to generate the data is described in the first paragraph in the section entitled "Kinase Knowledgebase (KKB)". In order to be more accessible for the reader, this paragraph should be encompassed in a separate section named "Materials and methods".
In Table 2 there are three columns with repeated headers. In order to remove any doubts, I would recommend the authors to clarify this issue. Otherwise, the data note is well written, kinases are indexed using the widely adopted Uniprot IDs and the references are updated. I recommend this data note for indexation and would like the authors to address the minor observations. high-quality kinase activity data. Providing access to over ¼ million data points on several of the most important kinases allows for an exciting insight into the relevance of these validated drug targets and the diversity of compounds affecting them. It is a promising trend that private companies are unlocking their proprietary data troves for the advancement of academic research. This is a nice Data Note that merits indexing in F1000Research.
A few minor typographical corrections: Table 2 : Three of the column names seem to be duplicated. No competing interests were disclosed.
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